Evidence map›Paper›PMID 37860081›Full record

ArticleGynecologic oncology reports2023

Hector S Porragas-Paseiro, Steven Johnson, Lindsay Brubaker, Brooke E Sanders

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Type IV pili ofEcoSal Plus · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Hector S Porragas-PaseiroUniversity of Colorado, Department of Obstetrics and Gynecology; Division of Gynecologic Oncology, USA.
Steven JohnsonUniversity of Colorado, Department of Infectious Diseases, USA.
Lindsay BrubakerUniversity of Colorado, Department of Obstetrics and Gynecology; Division of Gynecologic Oncology, USA.
Brooke E SandersUniversity of Colorado, Department of Obstetrics and Gynecology; Division of Gynecologic Oncology, USA.
Gynecologic Oncology Group · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Low-risk gestational trophoblastic neoplasia (GTN) is generally treated with single agent chemotherapy, including methotrexate (MTX) or dactinomycin. We present a case of a patient with low-risk GTN who underwent single agent MTX therapy, developed

Indexed as

Gestational trophoblastic neoplasiaMethotrexatePneumocystis Jirovecii Pneumonia

Identifiers

PMID37860081
PMCPMC10582284
OpenAlexW4387460793

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.